CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers
Open Access
- 4 February 2009
- Vol. 115 (7), 1395-1403
- https://doi.org/10.1002/cncr.24152
Abstract
BACKGROUND: There are limited data regarding unique clinical or laboratory features associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian cancers (EOC), particularly the relationship between CA‐125 antigen levels and prognosis. METHODS: A retrospective review of 7 previously reported Gynecologic Oncology Group phase 3 trials in patients with stage III/IV EOC was conducted. A variety of clinical parameters were examined, including the impact of baseline and changes in the CA‐125 level after treatment of CC and MU EOC on progression‐free (PFS) and overall survival (OS). RESULTS: Clinical outcomes among patients with advanced CC and MU EOC were significantly worse when compared with other cell types (median PFS, 9.7 vs 7.0 vs 16.7 months, respectively, P < .001; median OS, 19.4 vs 11.3 vs 40.5 months, respectively, P < .001). Suboptimal debulking was associated with significantly decreased PFS and OS among both. Although baseline CA‐125 values were lower in CC (median, 154 μ/mL) and MU (100 μ/mL), compared with other cell types (275 μ/mL), this level did not appear to influence outcome among these 2 specific subtypes of EOC. However, an elevated level of CA‐125 at the end of chemotherapy was significantly associated with decreased PFS and OS (P < .01 for all). CONCLUSIONS: Surgical debulking status is the most important variable at prechemotherapy predictive of prognosis among advanced CC and MU EOC patients. Changes in the CA‐125 levels at the end treatment as compared with baseline can serve as valid indicators of PFS and OS, and likely the degree of inherent chemosensitivity. Cancer 2009. © 2009 American Cancer Society.Keywords
This publication has 26 references indexed in Scilit:
- Phase III Randomized Trial of Intravenous Cisplatin Plus a 24- or 96-Hour Infusion of Paclitaxel in Epithelial Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2007
- Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition AnalysisClinical Cancer Research, 2004
- Mucinous Epithelial Ovarian Cancer: A Separate Entity Requiring Specific TreatmentJournal of Clinical Oncology, 2004
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated LevelsJournal of Clinical Oncology, 2001
- Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2001
- Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors [Ovarian Cancer]JNCI Journal of the National Cancer Institute, 2000
- CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancerBritish Journal of Cancer, 1999
- Evaluation of serum CA 125 levels in the monitoring of ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1987
- Prognostic factors in advanced ovarian carcinoma.Journal of Clinical Oncology, 1986